Next Article in Journal
Early Exercise Protects against Cerebral Ischemic Injury through Inhibiting Neuron Apoptosis in Cortex in Rats
Next Article in Special Issue
PAX2 Expression in Ovarian Cancer
Previous Article in Journal
The Role of Metallothionein in Oxidative Stress
Previous Article in Special Issue
HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines
Article Menu

Export Article

Open AccessCase Report
Int. J. Mol. Sci. 2013, 14(3), 6067-6073;

A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies

Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Shimane 6938501, Japan
Department of Gynecology, Ohki Memorial Kikuchi Cancer Clinic for Women, Tokorozawa, Saitama 3591133, Japan
Author to whom correspondence should be addressed.
Received: 17 February 2013 / Revised: 11 March 2013 / Accepted: 12 March 2013 / Published: 15 March 2013
(This article belongs to the Special Issue Genes and Pathways in the Pathogenesis of Ovarian Cancer)
View Full-Text   |   Download PDF [2733 KB, uploaded 19 June 2014]


Ovarian cancer treatment presently does not reflect molecular differences in histologic subtype. Ovarian clear cell carcinoma (OCCC) exhibits several differences in terms of molecular pathogenesis and tumor behavior from the more common, chemosensitive, serous carcinomas, which makes OCCC a candidate for targeted therapies. A 53-year-old Japanese woman was diagnosed with stage IIIc ovarian clear cell adenocarcinoma with marked chemoresistance to conventional regimens. She demonstrated a partial response to a multikinase inhibitor. The tumor was resistant to PI3K/mTOR pathway inhibitors despite harboring a PIK3CA mutation. The present case suggests a role for targeted therapies in the treatment of OCCC and a need for the identification of biomarkers that will predict response to targeted therapies. View Full-Text
Keywords: ovarian clear cell carcinoma; biomarkers; PIK3CA; mTOR inhibitor ovarian clear cell carcinoma; biomarkers; PIK3CA; mTOR inhibitor
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Rahman, M.; Nakayama, K.; Ishibashi, T.; Ishikawa, M.; Rahman, M.T.; Katagiri, H.; Katagiri, A.; Iida, K.; Kikuchi, Y.; Miyazaki, K. A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies. Int. J. Mol. Sci. 2013, 14, 6067-6073.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top